These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29701508)

  • 21. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Yang M; Galebach PJ; Signorovitch JE; Garg V
    Clin Exp Rheumatol; 2017; 35(5):791-798. PubMed ID: 28339358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.
    Ghabri S; Binard A; Pers YM; Maunoury F; Caro JJ
    Value Health; 2020 Apr; 23(4):461-470. PubMed ID: 32327163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.
    Linde L; Sørensen J; Østergaard M; Hetland ML
    J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars.
    Wu B; Song Y; Leng L; Bucala R; Lu LJ
    Clin Exp Rheumatol; 2015; 33(1):20-6. PubMed ID: 25438197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interest of modelling in rheumatoid arthritis.
    Beresniak A; Dupont DM; Becker JC; Merkesdal S
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S96-101. PubMed ID: 23078913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
    Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
    Iannazzo S; Benucci M; Favalli EG
    Clin Exp Rheumatol; 2018; 36(3):479-485. PubMed ID: 29352843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
    Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
    Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ; Brennan A; Ghatnekar O
    Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.
    Gissel C; Götz G; Repp H
    Z Rheumatol; 2016 Dec; 75(10):1006-1015. PubMed ID: 27080399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis.
    Ganz ML; Hansen BB; Valencia X; Strandberg-Larsen M
    J Med Econ; 2015 May; 18(5):366-75. PubMed ID: 25530467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
    Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
    Alemao E; Johal S; Al MJ; Rutten-van Mölken M
    Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up.
    Cárdenas MJ; de la Fuente S; Castro-Villegas MC; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérrez J; Escudero-Contreras A; Del Prado JR; Collantes-Estévez E; Font P
    Rheumatol Int; 2017 Oct; 37(10):1701-1708. PubMed ID: 28597307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.